German drugmaker Boehringer Ingelheim and Denmark’s Zealand Pharma have reported positive Phase 3 results for their experimental obesity drug survodutide, which met its primary cardiovascular safety endpoint in a trial involving 5,530 patients and delivered estimated weight loss of up to 13.7% at 72 weeks. However, about one in five patients receiving the drug stopped treatment because of gastrointestinal side effects.
ADVERTISEMENT
Tag Archive for: anti-obesity
Novo Nordisk will pay China’s Jiangsu Hengrui Pharmaceuticals $300 million (€264 million) upfront, in a deal worth up to $2.6 billion (€2.3 billion), for rights outside Greater China to HRS-1596, an experimental obesity and diabetes pill that the companies say could be taken once a week.
Italian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 receptor agonist from China’s Gan & Lee Pharmaceuticals dosed once every two weeks, for €62 million upfront, up to €664 million in milestones, and “double-digit” royalties. Menarini will handle regulatory submissions and commercialization across 39 European markets.
Denmark’s Novo Nordisk has signed a collaboration with Boston-based Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated metabolic diseases. Vivtex is eligible to receive upfront payments, research funding and milestone payments totalling up to $2.1 billion (approximately €1.78bn), as well as tiered royalties on net sales of any resulting products.





